Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

Phase 1 Completed 45 enrolled Chong Kun Dang Pharmaceutical

RandomizedCrossoverOpen-labelTreatment

Summary

This is a Randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of CKD-383 and the co-administration of CKD-501, D745, and D150 for healthy subjects in fed state

Timeline

Start: 2024-04-04
Primary completion: 2024-04-29
Completion: 2024-05-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-383	Unknown	—	Oral
Subject	Empagliflozin	Small molecule	25 mg	Oral
Subject	Lobeglitazone	Small molecule	0.5 mg	Oral
Subject	Metformin	Small molecule	1000 mg	Oral

Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.

Summary

Timeline

Drugs

Indications